NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

阿滋海默氏症的治療/診斷:全球市場

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

出版商 BCC Research 商品編碼 974122
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
阿滋海默氏症的治療/診斷:全球市場 Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
出版日期: 2020年11月27日內容資訊: 英文 88 Pages
簡介

阿滋海默氏症治療的全球市場將從2020年的48億美元增長到2025年的63億美元,從2020年到2025年的複合年增長率為5.5%。

北美阿滋海默氏症治療市場規模將從2020年的25億美元增長到2025年的33億美元,預計2020年至2025年的複合年增長率為5.6%。

亞太地區阿滋海默氏症治療市場的規模將從2020年的13億美元增長到2025年的17億美元,從2020年到2025年的複合年增長率為5.6%。

本報告對全球阿滋海默氏症治療和診斷市場進行了全面調查,包括市場規模和預測,市場機會,主要國家/地區和細分市場的市場分析和預測以及主要公司的概況。它提供。

目錄

第1章簡介

  • 調查目標/目的
  • 進行此調查的原因
  • 報告範圍
  • 來源
  • 調查方法
  • 分析師職業
  • BCC自定義調查
  • BCC研究相關報告

第2章摘要和重點

第3章概述

  • 阿滋海默氏症:定義和市場結構
  • 阿滋海默氏症的病理生理學
  • AD和澱粉樣蛋白級聯
  • AD和tauopathy
  • AD和神經遞質系統
  • 阿滋海默氏症的病因
  • 遺傳因素
  • 非遺傳因素
  • 阿滋海默氏症的流行病學
  • 發病年齡
  • 發病率,患病率和死亡率
  • AD的階段和嚴重性
  • 合併症
  • 阿滋海默氏症的診斷和治療
  • 阿滋海默氏症的診斷
  • AS的伴隨成像診斷
  • 用於澱粉樣蛋白可視化的CIDX技術
  • 用於TAU-NFT可視化的CIDX技術
  • 正在開發的tau示蹤劑的比較分析
  • CIDX技術:AB與Tau成像技術
  • 結論
  • AD藥物治療

第4章監管結構

  • 美國
  • 加速批准
  • 快速通道指定
  • 突破性治療藥物的指定
  • 優先審查
  • 管制物質法
  • 特殊協議評估
  • 新的監控和安全要求
  • 加拿大
  • 墨西哥
  • 歐洲
  • 亞太地區
  • 其他地區
  • 兌換情況

第5章市場動態

  • 市場增長促進者
  • 在診斷和藥物開發中使用生物標誌物
  • 大量藥品正在投放中
  • 市場限制
  • 品牌藥品專利到期和仿製藥的出現
  • 藥物開發失敗率高
  • 藥品開發成本高

第6章全球阿滋海默氏症治療市場

  • 市場概況
  • 阿滋海默氏症全球藥品市場:作用機理
  • 乙□膽鹼酯□抑制劑(AChEI)
  • NMDA拖動
  • 全球品牌/通用AD治療市場:按類型
  • 全球AD治療藥物市場:按AD階段劃分

第7章市場細分:按地區

  • 世界市場:按地區
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區
  • 產業結構
  • 常見AD治療的效果

第8章管道分析

  • 藥物開發過程概述
  • 第三階段
  • 第二階段
  • 第一階段
  • 贊助商

第9章公司簡介

  • ABBVIE
  • ACADIA PHARMACEUTICALS INC.
  • ALEMBIC PHARMACEUTICALS LTD.
  • ALEXZA PHARMACEUTICALS
  • ALKERMES PLC
  • ALLERGAN PLC
  • APOTEX INC.
  • ASTRAZENECA PLC
  • AUROBINDO PHARMA
  • AVANIR PHARMACEUTICALS INC.
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB CO.
  • BIOGEN
  • DAIICHI SANKYO CO., LTD.
  • DR. REDDY'S LABORATORIES LTD.
  • ELI LILLY AND CO.
  • EISAI CO., LTD.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • GEDEON RICHTER PLC
  • IMMUNOCELLULAR THERAPEUTICS LTD.
  • JOHNSON & JOHNSON
  • LANNETT CO., INC.
  • H. LUNDBECK A/S
  • LUPIN LTD.
  • MALLINCKRODT
  • MERCK & CO.
  • MYLAN NV
  • NEXTSOURCE BIOTECHNOLOGY LLC
  • NOVARTIS AG
  • OTSUKA HOLDINGS CO., LTD.
  • PFIZER INC.
  • SANOFI
  • SUMITOMO DAINIPPON PHARMA CO., LTD.
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • TORRENT PHARMACEUTICALS LTD.
  • UCB SA

第10章附錄:縮寫

目錄
Product Code: PHM062D

Highlights:

The global market for Alzheimer’s disease treatment should grow from $4.8 billion in 2020 to $6.3 billion by 2025 with a compound annual growth rate (CAGR) of 5.5% during the period of 2020-2025.

The North American market for Alzheimer’s disease treatment should grow from $2.5 billion in 2020 to $3.3 billion by 2025 with a CAGR of 5.6% during the period of 2020-2025.

The Asia-Pacific market for Alzheimer’s disease treatment should grow from $1.3 billion in 2020 to $1.7 billion by 2025 with a CAGR of 5.6% during the period of 2020-2025.

Report Scope:

The scope of this study encompasses the global and regional markets for Alzheimer's therapeutics and diagnostics. These markets are segmented by branded and generic drugs, and mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (AB) vaccines. Drugs are also segmented by the stage of Alzheimer's disease they treat, i.e., mild to moderate, severe and prodromal.

BCC Research analyzed each market and its applications, regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe, Asia-Pacific and Rest of the world (RoW).

Report Includes:

  • 27 tables
  • An overview of the global market for Alzheimer's disease (AD) therapeutics and diagnostics
  • Estimation of the market size and analyses of global market trends with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Detailed description of Alzheimer's disease and discussion on disease-related events, etiology and epidemiology covering prevalence and incidence rates
  • Identification of diagnostic tools and equipment; evaluation of important scientific and technological frameworks; and coverage of developments in the global market for Alzheimer's disease therapeutics and diagnostics.
  • Information on products that are currently available for the diagnosis and treatment of Alzheimer's disease as well as highlights of the promising new drug candidates and diagnostic imaging agents
  • Market share analysis of Alzheimer's disease therapeutics and diagnostics, by mechanism of action, disease stage and major geographical regions covering North America, Europe, APAC and Rest of the World
  • Detailed analysis of the current market trends, market forecast, drivers, challenges, and opportunities affecting market growth and discussion on regulatory and competitive elements that are affecting the future marketplace
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
  • Company profiles of major market players, including AbbVie, AstraZeneca Plc, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffmann-La Roche AG, GlaxoSmithKline, Johnson & Johnson, Pfizer Inc., Novartis and Sanofi

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

  • Alzheimer's Disease: Definition and Market Structure
  • Alzheimer's Disease Pathophysiology
  • AD and Amyloid Cascade
  • AD and Tauopathy
  • AD and Neurotransmitter Systems
  • Alzheimer's Disease Etiology
  • Genetic Factors
  • Non-Genetic Factors
  • Alzheimer's Disease Epidemiology
  • Age of Onset
  • Incidence, Prevalence and Mortality
  • Stages and Severity of AD
  • Comorbidities
  • Diagnosis and Treatment of Alzheimer's
  • Diagnosis of Alzheimer's
  • Companion Imaging Diagnostics for AS
  • CIDX Technologies for Amyloid Visualization
  • CIDX Technologies for TAU-NFT Visualization
  • Comparative Analysis of Tau Tracers in Development
  • CIDX Technologies: AB vs. Tau Imaging Technologies
  • Concluding Remarks
  • Pharmaceutical Treatment of AD

Chapter 4 Regulatory Structure

  • U.S.
  • Accelerated Approvals
  • Fast Track Designation
  • Breakthrough Therapy Designation
  • Priority Review
  • Controlled Substances Act
  • Special Protocol Assessments
  • New Surveillance and Safety Requirements
  • Canada
  • Mexico
  • Europe
  • Asia-Pacific
  • Rest of the World
  • Reimbursement Landscape

Chapter 5 Market Dynamics

  • Market Drivers
  • Use of Biomarkers in Diagnosis and Drug Development
  • Large Number of Drugs in the Pipeline
  • Market Restraints
  • Patent Expirations of Branded Drugs and Emergence of Generics
  • High Failure Rate in Drug Development
  • High Cost of Drug Development

Chapter 6 Global Markets for Alzheimer's Disease Therapeutics

  • Market Overview
  • Global Market for Alzheimer's Drugs by Mechanism of Action
  • Acetylcholinesterase Inhibitors (AChEIs)
  • NMDA Drugs
  • Global Market for Branded/Generic AD Therapeutics by Type
  • Global Market for AD Therapeutics by Stage of AD

Chapter 7 Market Breakdown by Region

  • Global Market for Alzheimer's Drugs by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
  • Industry Structure
  • Impact of Generic AD Therapeutics

Chapter 8 Pipeline Analysis

  • Overview of the Drug Development Process
  • Phase III
  • Phase II
  • Phase I
  • Trial Sponsors

Chapter 9 Company Profiles

  • ABBVIE
  • ACADIA PHARMACEUTICALS INC.
  • ALEMBIC PHARMACEUTICALS LTD.
  • ALEXZA PHARMACEUTICALS
  • ALKERMES PLC
  • ALLERGAN PLC
  • APOTEX INC.
  • ASTRAZENECA PLC
  • AUROBINDO PHARMA
  • AVANIR PHARMACEUTICALS INC.
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB CO.
  • BIOGEN
  • DAIICHI SANKYO CO., LTD.
  • DR. REDDY'S LABORATORIES LTD.
  • ELI LILLY AND CO.
  • EISAI CO., LTD.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • GEDEON RICHTER PLC
  • IMMUNOCELLULAR THERAPEUTICS LTD.
  • JOHNSON & JOHNSON
  • LANNETT CO., INC.
  • H. LUNDBECK A/S
  • LUPIN LTD.
  • MALLINCKRODT
  • MERCK & CO.
  • MYLAN NV
  • NEXTSOURCE BIOTECHNOLOGY LLC
  • NOVARTIS AG
  • OTSUKA HOLDINGS CO., LTD.
  • PFIZER INC.
  • SANOFI
  • SUMITOMO DAINIPPON PHARMA CO., LTD.
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • TORRENT PHARMACEUTICALS LTD.
  • UCB SA

Chapter 10 Appendix: Acronyms

List of Tables

  • Summary Table : Global Market for Alzheimer's Drugs, by Region, Through 2025
  • Table 1 : Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
  • Table 2 : Pharmacological Treatment of BPSD of Alzheimer's
  • Table 3 : Computerized Screening Tests Used in Detecting Cognitive Impairment
  • Table 4 : Brain Imaging Technologies and Application in the Alzheimer's Context
  • Table 5 : Global Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 6 : Global Market for Alzheimer's AChEIs Drugs, by Region, Through 2025
  • Table 7 : Global Market for Alzheimer's NMDA Drugs , by Region, Through 2025
  • Table 8 : Global Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 9 : Global Market for AD Therapeutics, by Disease Stage, Through 2025
  • Table 10 : Global Market for Late Stage/Severe AD Therapeutics, by Region, Through 2025
  • Table 11 : Global Market for Early/Middle Stage AD Therapeutics, by Region, Through 2025
  • Table 12 : Global Market for Alzheimer's Drugs, by Region, Through 2025
  • Table 13 : North American Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 14 : North American Market for Alzheimer's Drugs, by Country, Through 2025
  • Table 15 : North American Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 16 : European Market for Alzheimer's Drugs, by Country, Through 2025
  • Table 17 : European Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 18 : European Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 19 : Asia-Pacific Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 20 : Asia-Pacific Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 21 : Global Ranking of Leading Players in Alzheimer's Disease Drugs
  • Table 22 : Agents in Phase III of Alzheimer's Disease Drug Development
  • Table 23 : Agents in Phase II of Alzheimer's Disease Drug Development
  • Table 24 : Agents in Phase I of Alzheimer's Disease Drug Development
  • Table 25 : Trial Sponsor for Each Phase of Alzheimer's Disease Drug Development
  • Table 26 : Acronyms Used in This Report

List of Figures

  • Summary Figure : Global Market Shares of Alzheimer's Drugs, by Region, 2019
  • Figure 1 : Trends in Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
  • Figure 2 : Pharmaceutical Regulatory Pathways in the U.S. and Europe
  • Figure 3 : Global Market for Alzheimer's AChEIs Drugs, 2019-2025
  • Figure 4 : Global Market for Alzheimer's NMDA Drugs, 2019-2025
  • Figure 5 : Global Market Shares of Alzheimer's Drugs, by Region, 2019
  • Figure 6 : North American Market for Alzheimer's Drugs, 2019-2025
  • Figure 7 : European Market for Alzheimer's Drugs, 2019-2025
  • Figure 8 : Asia-Pacific Market for Alzheimer's Drugs, 2019-2025
  • Figure 9 : South American Market for Alzheimer's Drugs, 2019-2025
  • Figure 10 : Middle Eastern and African Market for Alzheimer's Drugs, 2019-2025